Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Viatris Just Sold Off 3 Key Segments. Is It Still a Buy?
Viatris Just Sold Off 3 Key Segments. Is It Still a Buy?
Viatris Just Sold Off 3 Key Segments. Is It Still a Buy?
Submitted by
admin
on October 13, 2023 - 10:10am
Source:
Motley Fool
News Tags:
Viatris
APIs
Women's Health
OTC
Headline:
Viatris Just Sold Off 3 Key Segments. Is It Still a Buy?
snippet:
Viatris is advancing in its plan to become leaner and pay off its debt.
To do so, it's offloading a trio of non-core business segments.
However, it's still retaining all of its most lucrative medicines.
Do Not Allow Advertisers to Use My Personal information
